



Date: January 17, 2023

Subject Line: Community statement regarding Biogen and Alcyone collaboration

To: SMA Europe

Dear SMA Community,

In response to your request, we are pleased to share the news that Biogen has announced a license and collaboration agreement with the US company, Alcyone Therapeutics, to evaluate further its investigational implantable device called ThecaFlex DRx™.

About the device

ThecaFlex DRx offers an alternative means of nusinersen administration for people with SMA. Once implanted, the device remains permanently beneath the skin to deliver an injection of nusinersen into the intrathecal space – the fluid-filled space between the thin layers of tissue that cover the spinal cord. Currently, nusinersen is given via lumbar puncture – a thin needle that is inserted between the bones of the lower spine.

Biogen and Alcyone will jointly collaborate on the clinical development plans for the device in people with SMA receiving nusinersen, gathering input from healthcare professionals and patient advocacy groups. Community updates on potential clinical trials will be provided as appropriate and when requested.

Please get in touch if you have further questions.

Best regards,

Michaela Hrdlickova

Director Patient Advocacy SMA, Europe/Canada/Partner Markets, Biogen